Abstract 1325
Case Summary
A 79-year-old woman was treated in our ward for an invasive carcinoma of no special type (NST) of her left breast, discovered by a spontaneous apparition of a localized ecchymotic lesion of the breast. The unique calling-spot was this 4x5cm homogeneous oval shape purpura without any notion of trauma, stable for months. The patient have no medical history of thrombopenia nor allergies. The physical exam was poor, without any palpable breast lesion. A not well defined solid para-areolar structure of 11 mm was found during the senological assessment. Biopsies were performed and highlighted a grade II NST, triple negative, Ki67 15%. The axillary cytology was positive. Subsequently this atypical presentation, a punch biopsy was performed on the ecchymosis. The histology showed the presence of dermal lymphatic carcinomatous emboli that may correspond to a mammary origin, and blood extravasations in the dermis, explaining the ecchymotic aspect. The PET-CT was negative. Neo-adjuvant chemotherapy was decided before mastectomy and axillary dissection. This was a rare clinical presentation of a locally advanced breast cancer without any reported similar case. Usually, the presence of emboli with carcinoma cells obstructing lymph ducts is associated with an inflammatory breast cancer. The presence of tumor emboli in the lymph ducts comes out in favor of the diagnosis but it is not mandatory. Moreover, dermal lymphatic invasion without typical clinical presentation isn’t sufficient to diagnose a carcinomatous mastitis. A main criterion is the rapidity of the worsening of the symptoms which is not obvious in that case with a stagnation of the skin lesion for months. The skin lesion of our patient could be suspected of being a mammary angiosarcoma. This possibility was quickly put aside with the absence of vascular tumoral proliferation on the biopsies. Every acute purpura is a serious condition to diagnose in emergency to not miss a meningococcemia, a severe thrombopenia or an infective endocarditis. Any isolated purpura of the breast must set off a senological assessment and cutaneous biopsies, when the clinical presentation is atypical and in absence of patent diagnosis, in order not to miss an underlying, locally advanced neoplasia.
Editorial acknowledgement
Clinical trial identification
Resources from the same session
780 - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
Presenter: Xiu Chen
Session: Poster display - Cocktail
Resources:
Abstract
782 - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
Presenter: Junchen Hou
Session: Poster display - Cocktail
Resources:
Abstract
916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
Presenter: Sourav Nandi
Session: Poster display - Cocktail
Resources:
Abstract
928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea
Presenter: In Hae Park
Session: Poster display - Cocktail
Resources:
Abstract
1274 - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
Presenter: Savitha Rajarajan
Session: Poster display - Cocktail
Resources:
Abstract
165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Presenter: YiHui Li
Session: Poster display - Cocktail
Resources:
Abstract
561 - Quality of life and psychosocial needs of metastatic breast cancer patients
Presenter: Tahir Mehmood
Session: Poster display - Cocktail
Resources:
Abstract
697 - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Presenter: Yong Shen
Session: Poster display - Cocktail
Resources:
Abstract
784 - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
Presenter: Mei Wang
Session: Poster display - Cocktail
Resources:
Abstract
921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
Presenter: Junichiro Watanabe
Session: Poster display - Cocktail
Resources:
Abstract